ATE365165T1 - Diaminopyrimidine und deren verwendung als angiogenesehemmer - Google Patents
Diaminopyrimidine und deren verwendung als angiogenesehemmerInfo
- Publication number
- ATE365165T1 ATE365165T1 AT03743709T AT03743709T ATE365165T1 AT E365165 T1 ATE365165 T1 AT E365165T1 AT 03743709 T AT03743709 T AT 03743709T AT 03743709 T AT03743709 T AT 03743709T AT E365165 T1 ATE365165 T1 AT E365165T1
- Authority
- AT
- Austria
- Prior art keywords
- diaminopyrimidines
- angiogenesis inhibitors
- benzimidazole derivatives
- inhibitors
- methods
- Prior art date
Links
- 229940121369 angiogenesis inhibitor Drugs 0.000 title 1
- 239000004037 angiogenesis inhibitor Substances 0.000 title 1
- 229940058936 antimalarials diaminopyrimidines Drugs 0.000 title 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 2
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 abstract 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 abstract 1
- 229940091171 VEGFR-2 tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36074102P | 2002-03-01 | 2002-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE365165T1 true ATE365165T1 (de) | 2007-07-15 |
Family
ID=27789011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03743709T ATE365165T1 (de) | 2002-03-01 | 2003-02-28 | Diaminopyrimidine und deren verwendung als angiogenesehemmer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7338959B2 (de) |
| EP (1) | EP1487824B1 (de) |
| JP (1) | JP2005524668A (de) |
| AT (1) | ATE365165T1 (de) |
| AU (1) | AU2003220970A1 (de) |
| CA (1) | CA2477505A1 (de) |
| DE (1) | DE60314500T2 (de) |
| ES (1) | ES2290479T3 (de) |
| MX (1) | MXPA04008458A (de) |
| WO (1) | WO2003074515A1 (de) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| ATE447404T1 (de) * | 2002-03-29 | 2009-11-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
| BR0313059B8 (pt) | 2002-07-29 | 2021-07-27 | Rigel Pharmaceuticals | composto, e, composição farmacêutica |
| US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| EP2258365B1 (de) * | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Verwendung von organischen verbindungen zur immunstärkung |
| CN102358738A (zh) | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
| DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| DE10342503A1 (de) * | 2003-09-12 | 2005-04-14 | Merck Patent Gmbh | Benzyl-Benzimidazolylderivate |
| BRPI0414544A (pt) * | 2003-09-18 | 2006-11-07 | Novartis Ag | 2,4-di-(fenilamino) pirimidinas úteis no tratamento de transtornos proliferativos |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| WO2005079791A1 (en) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
| US7456176B2 (en) * | 2004-04-08 | 2008-11-25 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| US7652051B2 (en) | 2004-08-25 | 2010-01-26 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| EP1799652A1 (de) | 2004-10-13 | 2007-06-27 | Wyeth | N-benzolsulfonyl-substituierte anilino-pyrimidin-analoga |
| JP5095409B2 (ja) | 2004-11-24 | 2012-12-12 | ライジェル ファーマシューティカルズ， インコーポレイテッド | スピロ２，４−ピリミジンジアミン化合物およびその使用 |
| EP1674469A1 (de) * | 2004-12-22 | 2006-06-28 | Schering Aktiengesellschaft | Sulfonamid-Makrozyclen als Tie2-Hemmer |
| EP1674470A1 (de) * | 2004-12-22 | 2006-06-28 | Schering Aktiengesellschaft | Sulfonamid-Makrozyclen als Tie2-Hemmer |
| EP1674466A1 (de) * | 2004-12-27 | 2006-06-28 | 4Sc Ag | 2,5- und 2-6-disubstituierte Benzazol-Derivate zur Verwendung als Protein Kinase Inhibitoren |
| US7576090B2 (en) | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
| JP4801096B2 (ja) | 2005-01-19 | 2011-10-26 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
| US20060247263A1 (en) * | 2005-04-19 | 2006-11-02 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| CA2611720A1 (en) * | 2005-06-08 | 2006-12-14 | Targegen, Inc. | Methods and compositions for the treatment of ocular disorders |
| EP1904457B1 (de) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur inhibierung des jak-pfades |
| US7528143B2 (en) * | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US20070161645A1 (en) * | 2005-11-02 | 2007-07-12 | Targegen, Inc. | Thiazole inhibitors targeting resistant kinase mutations |
| JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| MX2008013990A (es) | 2006-05-09 | 2009-01-29 | Pfizer Prod Inc | Derivados de cicloalquilamino acidos. |
| US8030487B2 (en) | 2006-07-07 | 2011-10-04 | Targegen, Inc. | 2-amino—5-substituted pyrimidine inhibitors |
| CA2662580C (en) | 2006-09-11 | 2013-05-21 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| EP2154967B9 (de) | 2007-04-16 | 2014-07-23 | Hutchison Medipharma Enterprises Limited | Pyrimidinderivate |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| JP5270553B2 (ja) * | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| KR20100132550A (ko) | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| MX2010011463A (es) | 2008-04-16 | 2011-06-03 | Portola Pharm Inc | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| CZ302548B6 (cs) * | 2008-10-22 | 2011-07-07 | Zentiva, A.S. | Zpusob výroby 5-amino-2-[(4-methoxy-3-methyl-2-pyridyl)methylthio]-1H-benzimidazolu a 5-(1H-pyrrol-1-yl)-2-[(4-methoxy-3-methyl-2-pyridyl)methylthio]-1H-benzimidazolu |
| US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| CA2763633A1 (en) * | 2009-05-27 | 2010-12-02 | Gary T. Wang | Pyrimidine inhibitors of kinase activity |
| BR112012029647A2 (pt) | 2010-05-21 | 2016-08-02 | Chemilia Ab | novos derivados de pirimidinas |
| AU2011255218B2 (en) | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| EP2635557A2 (de) | 2010-11-01 | 2013-09-11 | Portola Pharmaceuticals, Inc. | Nicotinamide als jak-kinasemodulatoren |
| US20130317029A1 (en) | 2010-11-01 | 2013-11-28 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
| CA2816219C (en) | 2010-11-01 | 2019-10-29 | Portola Pharmaceuticals, Inc. | Nicotinamides as syk modulators |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| UY33779A (es) | 2010-12-10 | 2012-07-31 | Boehringer Ingelheim Int | ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas? |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
| US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
| JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ | 新規のピリミジン誘導体 |
| WO2013054351A1 (en) * | 2011-08-08 | 2013-04-18 | Cadila Healthcare Limited | Heterocyclic compounds |
| WO2013024427A1 (en) * | 2011-08-16 | 2013-02-21 | Glenmark Pharmaceuticals S.A. | Novel urea derivatives as tec kinase inhibitors and uses thereof |
| EP2751093A1 (de) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclische verbindungen und ihre verwendung |
| SG11201402570QA (en) | 2011-11-23 | 2014-06-27 | Portola Pharm Inc | Pyrazine kinase inhibitors |
| US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
| US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
| US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
| US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
| US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| BR112016018604A2 (pt) | 2014-02-11 | 2017-08-08 | Bayer Pharma AG | Benzimidazol-2-aminas como inibidores de midh1 |
| CA2939021C (en) | 2014-02-11 | 2022-07-12 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| KR102494596B1 (ko) * | 2014-07-31 | 2023-01-31 | 재단법인 한국파스퇴르연구소 | 2-아미노-벤즈이미다졸 유도체 및 5-리폭시게나아제 및/또는 프로스타글란딘 e 합성효소 억제제로서의 이들의 용도 |
| WO2016062677A1 (en) | 2014-10-23 | 2016-04-28 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines as midh1 inhibitors |
| EP3209660B1 (de) | 2014-10-23 | 2020-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 1-cyclohexyl-2-phenylaminobenzimidazole als midh1-inhibitoren zur behandlung von tumoren |
| CN107531652A (zh) | 2015-03-31 | 2018-01-02 | 精化株式会社 | 芳香族二胺及其中间体和它们的制造方法 |
| US10647689B2 (en) * | 2015-04-28 | 2020-05-12 | Sanford Burnham Prebys Medical Discovery Institute | Apelin receptor agonists and methods of use thereof |
| EP3303302B1 (de) | 2015-06-08 | 2019-03-20 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazole als midh1-inhibitoren |
| US10414734B2 (en) | 2015-07-16 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors |
| WO2021038419A1 (en) * | 2019-08-23 | 2021-03-04 | Insilico Medicine Ip Limited | Kinase inhibitors and methods of synthesis and treatment |
| US12293809B2 (en) | 2019-08-23 | 2025-05-06 | Insilico Medicine Ip Limited | Workflow for generating compounds with biological activity against a specific biological target |
| EP4237423B1 (de) | 2020-11-02 | 2024-12-11 | Boehringer Ingelheim International GmbH | Substituierte 1h-pyrazolo[4,3-c]pyridine und derivate als egfr-inhibitoren |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1109555A4 (de) * | 1998-08-31 | 2001-11-21 | Merck & Co Inc | Neue angiogeneseinhibitoren |
| ES2556946T3 (es) | 2000-12-21 | 2016-01-21 | Novartis Ag | Pirimidinaminas como moduladores de la angiogénesis |
-
2003
- 2003-02-28 US US10/506,447 patent/US7338959B2/en not_active Expired - Fee Related
- 2003-02-28 MX MXPA04008458A patent/MXPA04008458A/es active IP Right Grant
- 2003-02-28 EP EP03743709A patent/EP1487824B1/de not_active Expired - Lifetime
- 2003-02-28 ES ES03743709T patent/ES2290479T3/es not_active Expired - Lifetime
- 2003-02-28 AT AT03743709T patent/ATE365165T1/de not_active IP Right Cessation
- 2003-02-28 CA CA002477505A patent/CA2477505A1/en not_active Abandoned
- 2003-02-28 DE DE60314500T patent/DE60314500T2/de not_active Expired - Fee Related
- 2003-02-28 WO PCT/US2003/006022 patent/WO2003074515A1/en not_active Ceased
- 2003-02-28 JP JP2003572983A patent/JP2005524668A/ja active Pending
- 2003-02-28 AU AU2003220970A patent/AU2003220970A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003220970A1 (en) | 2003-09-16 |
| CA2477505A1 (en) | 2003-09-12 |
| US7338959B2 (en) | 2008-03-04 |
| WO2003074515A1 (en) | 2003-09-12 |
| DE60314500D1 (de) | 2007-08-02 |
| EP1487824B1 (de) | 2007-06-20 |
| DE60314500T2 (de) | 2008-02-07 |
| US20050234083A1 (en) | 2005-10-20 |
| MXPA04008458A (es) | 2004-12-06 |
| EP1487824A1 (de) | 2004-12-22 |
| ES2290479T3 (es) | 2008-02-16 |
| JP2005524668A (ja) | 2005-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
| NO2022001I1 (no) | Pazopanib | |
| CY1112281T1 (el) | Αναστολεις διπεπτιδυλ πεπτιδασης για τη θεραπεια του διαβητη | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| CY1115745T1 (el) | Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου | |
| JO2534B1 (en) | Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| ATE403657T1 (de) | Chemische verbindungen | |
| DE60137307D1 (de) | Substituierte sapogenine und ihre verwendung | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| NO20055894L (no) | Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer | |
| CY1113413T1 (el) | Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης | |
| MX272108B (es) | Heterociclos sustituidos. | |
| CY1105879T1 (el) | Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
| DE60112742D1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| ATE213233T1 (de) | Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit | |
| NO20060420L (no) | 2-aminobenzoylderivater | |
| DE60324387D1 (de) | Verwendung von amylin, amylinanaloga und amylin derivaten zur behandlung von dyslipidämie und hypertriglyceridämie | |
| DE60228295D1 (de) | Chemische verbindungen | |
| CY1106540T1 (el) | Ετεροκυλικα υποκατεστημενες στη θεση 3 πιπεριδινο-2,6-διονες | |
| ATE272400T1 (de) | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren | |
| SE0202608D0 (sv) | New sequences | |
| ATE293107T1 (de) | Luminacine analoge und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |